Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer

被引：0
|
作者：
Maria Karsten
Michelle Stempel
Julia Radosa
Sujata Patil
Tari A. King
机构：
[1] Memorial Sloan Kettering Cancer Center,Breast Service, Department of Surgery
[2] Memorial Sloan Kettering Cancer Center,Department of Epidemiology and Biostatistics
来源：
Annals of Surgical Oncology | 2016年 / 23卷
关键词：
Breast Cancer; Breast Cancer Mortality; Recurrence Score; Bilateral Breast Cancer; Progesterone Receptor Expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：471 / 476
页数：5
相关论文
共 50 条
  • [31] Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the BC experience
    Baxter, E.
    Gondara, L.
    Lohrisch, C.
    Chia, S.
    Gelmon, K.
    Hayes, M.
    Davidson, A.
    Tyldesley, S.
    CURRENT ONCOLOGY, 2015, 22 (03) : 192 - 198
  • [32] Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database
    Megan C. Roberts
    Dave P. Miller
    Steven Shak
    Valentina I. Petkov
    Breast Cancer Research and Treatment, 2017, 163 : 303 - 310
  • [33] Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad, Juhi
    Jacobson, Allyson F.
    Estabrook, Alison
    Smith, Sharon Rosenbaum
    Boolbol, Susan K.
    Feldman, Sheldon M.
    Osborne, Michael P.
    Boachie-Adjei, Kwadwo
    Twardzik, Wendy
    Tartter, Paul I.
    AMERICAN JOURNAL OF SURGERY, 2008, 196 (04): : 527 - 529
  • [34] The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre
    McVeigh, Terri Patricia
    Hughes, Lauren M.
    Miller, Nicola
    Sheehan, Margaret
    Keane, Maccon
    Sweeney, Karl J.
    Kerin, Michael J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (16) : 2763 - 2770
  • [35] Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database
    Roberts, Megan C.
    Miller, Dave P.
    Shak, Steven
    Petkov, Valentina I.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (02) : 303 - 310
  • [36] The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience
    Valerie E. Crolley
    Husam Marashi
    Shabbir Rawther
    Bhawna Sirohi
    Marina Parton
    Janine Graham
    Anup Vinayan
    Stephanie Sutherland
    Anne Rigg
    Anshu Wadhawan
    Catherine Harper-Wynne
    Emma Spurrell
    Hannah Bond
    Fharat Raja
    Judy King
    Breast Cancer Research and Treatment, 2020, 180 : 809 - 817
  • [37] Economic evaluation of gene expression assays for breast cancer applying Oncotype DX (R)
    Thiem, Helena
    Lux, Michael P.
    Rebscher, Herbert
    Potempa, Christoph
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2018, 23 (04): : 230 - 235
  • [38] Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score
    Wilson, Parker C.
    Chagpar, Anees B.
    Cicek, Ali F.
    Bossuyt, Veerle
    Buza, Natalia
    Mougalian, Sarah
    Killelea, Brigid K.
    Patel, Natalie
    Harigopal, Malini
    BREAST JOURNAL, 2018, 24 (06): : 976 - 980
  • [39] Oncotype DX in Breast Cancer Management: Insights and Outcomes From the United Arab Emirates
    Ameri, Mouza A.
    Shanbhag, Nandan M.
    Bin Sumaida, Abdulrahman
    Ansari, Jawaher
    Trad, Diaeddine A.
    Dawoud, Emad A.
    Balaraj, Khalid
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [40] Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score
    Zhang, Michelle
    Sadinski, Meredith
    Haddad, Dana
    Bae, Min Sun
    Martinez, Danny
    Morris, Elizabeth A.
    Gibbs, Peter
    Sutton, Elizabeth J.
    FRONTIERS IN ONCOLOGY, 2021, 10
12345